{"nctId":"NCT02585778","briefTitle":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","startDateStruct":{"date":"2015-10-23","type":"ACTUAL"},"conditions":["Hypercholesterolaemia"],"count":517,"armGroups":[{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Lipid-Modifying Therapy (LMT)","Drug: Antihyperglycemic Drug"]},{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Lipid-Modifying Therapy (LMT)","Drug: Antihyperglycemic Drug"]}],"interventions":[{"name":"Alirocumab","otherNames":["Praluent","SAR236553","REGN727"]},{"name":"Placebo","otherNames":[]},{"name":"Lipid-Modifying Therapy (LMT)","otherNames":[]},{"name":"Antihyperglycemic Drug","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participants diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (Week -3).\n* Signed written informed consent\n* Participants with type 1 or type 2 diabetes treated with insulin whose LDL-C levels were not adequately controlled with maximally tolerated lipid-modifying therapy\n* LDL-C of 70 mg/dL or greater\n* 18 years of age or more\n* Glycosylated hemoglobin (HbA1c) less than 10%\n* History of cardiovascular disease (including coronary heart disease \\[CHD\\] and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor\n\nExclusion criteria:\n\n* Not on a stable dose of statin or other lipid modifying therapy for at least 4 weeks prior to screening or from screening to randomization, unless statin intolerant\n* Triglycerides \\>400 mg/dL\n* Estimated glomerular filtration rate (eGFR) \\<15 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) equation\n* Currently received or planned to receive renal replacement therapy (for example, hemodialysis)\n* Change in weight of more than 5 kilograms within the prior 2 months\n* Not on a stable dose/regimen of insulin or other antidiabetic drugs for the past 3 months or planned to intensify insulin regimen during the study\n* Not treated with insulin for at least 6 months\n* Planned to start new lipid modifying therapy or change dose of current lipid modifying therapy during the study\n* Body mass index (BMI) \\>45 kg/m² or planned to undergo bariatric surgery, weight loss program, or initiate weight loss drugs during the study\n* History of recent decompensation of diabetes within the prior 2 months (for example, diabetic ketoacidosis)\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","description":"Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.8","spread":"3.7"},{"groupId":"OG001","value":"-3.9","spread":"5.3"},{"groupId":"OG002","value":"-48.2","spread":"1.6"},{"groupId":"OG003","value":"0.8","spread":"2.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)","description":"Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null},{"groupId":"OG001","value":"64.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.8","spread":"3.7"},{"groupId":"OG001","value":"-3.2","spread":"5.3"},{"groupId":"OG002","value":"-50.9","spread":"1.6"},{"groupId":"OG003","value":"0.7","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis","description":"Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.4","spread":"3.7"},{"groupId":"OG001","value":"-1.1","spread":"5.4"},{"groupId":"OG002","value":"-43.3","spread":"1.6"},{"groupId":"OG003","value":"2.4","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.4","spread":"3.5"},{"groupId":"OG001","value":"-4.5","spread":"5.0"},{"groupId":"OG002","value":"-48.8","spread":"1.4"},{"groupId":"OG003","value":"1.4","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Measured LDL-C at Week 12 - ITT Analysis","description":"Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.7","spread":"3.6"},{"groupId":"OG001","value":"-4.0","spread":"5.1"},{"groupId":"OG002","value":"-44.8","spread":"1.4"},{"groupId":"OG003","value":"-0.8","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.9","spread":"3.3"},{"groupId":"OG001","value":"-3.2","spread":"4.8"},{"groupId":"OG002","value":"-37.9","spread":"1.4"},{"groupId":"OG003","value":"0.7","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.4","spread":"3.0"},{"groupId":"OG001","value":"-0.4","spread":"4.3"},{"groupId":"OG002","value":"-33.4","spread":"1.3"},{"groupId":"OG003","value":"3.3","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.9","spread":"2.5"},{"groupId":"OG001","value":"-0.7","spread":"3.6"},{"groupId":"OG002","value":"-26.8","spread":"1.0"},{"groupId":"OG003","value":"0.8","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"76.4","spread":null},{"groupId":"OG003","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <50 mg/dL (1.3 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach (for T1DM participants) and multiple imputation approach model (for T2DM participants) including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). The maximum likelihood estimate did not exist as response rate was zero in a treatment group of T1DM participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"50.7","spread":null},{"groupId":"OG003","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated Non-HDL-C <100 mg/dL at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":null},{"groupId":"OG001","value":"22.9","spread":null},{"groupId":"OG002","value":"70.9","spread":null},{"groupId":"OG003","value":"13.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated Non-HDL-C <80 mg/dL at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"52.3","spread":null},{"groupId":"OG003","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach for handling of missing data followed by robust regression model. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","spread":"3.8"},{"groupId":"OG001","value":"-4.3","spread":"5.3"},{"groupId":"OG002","value":"-19.0","spread":"1.6"},{"groupId":"OG003","value":"-0.5","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"2.4"},{"groupId":"OG001","value":"7.3","spread":"3.5"},{"groupId":"OG002","value":"8.1","spread":"1.0"},{"groupId":"OG003","value":"3.7","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from multiple imputation approach for handling of missing data followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"4.7"},{"groupId":"OG001","value":"1.9","spread":"6.7"},{"groupId":"OG002","value":"-5.7","spread":"2.0"},{"groupId":"OG003","value":"0.0","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C Particle Number at Week 24 - ITT Analysis","description":"LDL-C particle number was calculated from lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.4","spread":"3.2"},{"groupId":"OG001","value":"-4.4","spread":"4.6"},{"groupId":"OG002","value":"-38.3","spread":"1.3"},{"groupId":"OG003","value":"1.9","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C Particle Size at Week 24 - ITT Analysis","description":"LDL-C particle size was calculated from lipid subfractions by NMR spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"0.3"},{"groupId":"OG001","value":"0.8","spread":"0.5"},{"groupId":"OG002","value":"-2.8","spread":"0.1"},{"groupId":"OG003","value":"-0.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24 - ITT Analysis","description":"Absolute change = HbA1c value at specified weeks minus HbA1c value at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.46"},{"groupId":"OG001","value":"-0.22","spread":"0.39"},{"groupId":"OG002","value":"-0.04","spread":"0.57"},{"groupId":"OG003","value":"0.00","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.60"},{"groupId":"OG001","value":"-0.23","spread":"0.36"},{"groupId":"OG002","value":"0.18","spread":"0.74"},{"groupId":"OG003","value":"0.06","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in HbA1c at Weeks 12 and 24 - On-Treatment Analysis","description":"Absolute change = HbA1c value at specified weeks minus HbA1c value at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.46"},{"groupId":"OG001","value":"-0.22","spread":"0.39"},{"groupId":"OG002","value":"-0.04","spread":"0.57"},{"groupId":"OG003","value":"0.00","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.61"},{"groupId":"OG001","value":"-0.27","spread":"0.34"},{"groupId":"OG002","value":"0.18","spread":"0.74"},{"groupId":"OG003","value":"0.06","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 24 - ITT Analysis","description":"Absolute change = FPG value at specified weeks minus FPG value at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"4.44"},{"groupId":"OG001","value":"0.45","spread":"4.73"},{"groupId":"OG002","value":"0.25","spread":"2.73"},{"groupId":"OG003","value":"0.13","spread":"2.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"5.20"},{"groupId":"OG001","value":"0.81","spread":"4.21"},{"groupId":"OG002","value":"0.52","spread":"3.43"},{"groupId":"OG003","value":"0.55","spread":"2.62"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in FPG at Weeks 12 and 24 - On-Treatment Analysis","description":"Absolute change = FPG value at specified weeks minus FPG value at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"4.44"},{"groupId":"OG001","value":"0.45","spread":"4.73"},{"groupId":"OG002","value":"0.22","spread":"2.70"},{"groupId":"OG003","value":"0.15","spread":"2.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"5.24"},{"groupId":"OG001","value":"0.71","spread":"4.19"},{"groupId":"OG002","value":"0.52","spread":"3.47"},{"groupId":"OG003","value":"0.48","spread":"2.53"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - ITT Analysis","description":"Absolute change = total daily insulin dose at specified weeks minus baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"48.7"},{"groupId":"OG001","value":"-1.3","spread":"9.6"},{"groupId":"OG002","value":"0.2","spread":"7.9"},{"groupId":"OG003","value":"1.4","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"11.3"},{"groupId":"OG001","value":"-0.8","spread":"9.8"},{"groupId":"OG002","value":"2.2","spread":"14.8"},{"groupId":"OG003","value":"1.6","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - On-Treatment Analysis","description":"Absolute change = total daily insulin dose at specified weeks minus baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"48.7"},{"groupId":"OG001","value":"-1.3","spread":"9.6"},{"groupId":"OG002","value":"0.2","spread":"7.9"},{"groupId":"OG003","value":"1.4","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"11.3"},{"groupId":"OG001","value":"-0.8","spread":"9.8"},{"groupId":"OG002","value":"1.7","spread":"11.7"},{"groupId":"OG003","value":"1.6","spread":"11.5"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - ITT Analysis","description":"Absolute change = daily insulin dose/kg at specified weeks minus baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.5"},{"groupId":"OG001","value":"0.0","spread":"0.1"},{"groupId":"OG002","value":"0.0","spread":"0.1"},{"groupId":"OG003","value":"0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.1"},{"groupId":"OG001","value":"0.0","spread":"0.1"},{"groupId":"OG002","value":"0.0","spread":"0.2"},{"groupId":"OG003","value":"0.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - On-Treatment Analysis","description":"Absolute change = daily insulin dose/kg at specified weeks minus baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.5"},{"groupId":"OG001","value":"0.0","spread":"0.1"},{"groupId":"OG002","value":"0.0","spread":"0.1"},{"groupId":"OG003","value":"0.0","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.1"},{"groupId":"OG001","value":"0.0","spread":"0.1"},{"groupId":"OG002","value":"0.0","spread":"0.1"},{"groupId":"OG003","value":"0.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - ITT Analysis","description":"Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified weeks minus baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0.1"},{"groupId":"OG003","value":"0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0.3"},{"groupId":"OG003","value":"0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis","description":"Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified weeks minus baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0.1"},{"groupId":"OG003","value":"0","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0.3"},{"groupId":"OG003","value":"0","spread":"0.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":344},"commonTop":["Nasopharyngitis"]}}}